Rt-PA in the Treatment of Acute Ischemic Stroke

April 30, 2014 updated by: Boehringer Ingelheim

ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset

To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to placebo-treated patients will result in an improved clinical outcome without increase of fatality rate.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

821

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Graz, Austria
        • 135.312.43004 Boehringer Ingelheim Investigational Site
      • Innsbruck, Austria
        • 135.312.43007 Boehringer Ingelheim Investigational Site
      • Klagenfurt, Austria
        • 135.312.43010 Boehringer Ingelheim Investigational Site
      • Linz, Austria
        • 135.312.43001 Boehringer Ingelheim Investigational Site
      • Linz, Austria
        • 135.312.43012 Boehringer Ingelheim Investigational Site
      • Linz, Austria
        • 135.312.43013 Boehringer Ingelheim Investigational Site
      • Ma.Gugging/Klosterneuburg, Austria
        • 135.312.43008 Boehringer Ingelheim Investigational Site
      • Salzburg, Austria
        • 135.312.43006 Boehringer Ingelheim Investigational Site
      • St. Pölten, Austria
        • 135.312.43003 Boehringer Ingelheim Investigational Site
      • Wien, Austria
        • 135.312.43002 Boehringer Ingelheim Investigational Site
  • Belgium
      • Aalst, Belgium
        • 135.312.32006 O.L. Vrouwziekenhuis
      • Anderlecht, Belgium
        • 135.312.32002 Boehringer Ingelheim Investigational Site
      • Antwerpen, Belgium
        • 135.312.32014 Boehringer Ingelheim Investigational Site
      • Brugge, Belgium
        • 135.312.32001 Boehringer Ingelheim Investigational Site
      • Kortrijk, Belgium
        • 135.312.32011 Boehringer Ingelheim Investigational Site
      • Leuven, Belgium
        • 135.312.32005 Boehringer Ingelheim Investigational Site
      • Yvoir (Godinne), Belgium
        • 135.312.32016 Boehringer Ingelheim Investigational Site
  • Czech Republic
      • Ostrava, Czech Republic
        • 135.312.42001 Boehringer Ingelheim Investigational Site
      • Ostrava-Vitkovice, Czech Republic
        • 135.312.42004 Boehringer Ingelheim Investigational Site
      • Prague 5, Czech Republic
        • 135.312.42002 Boehringer Ingelheim Investigational Site
  • Denmark
      • Aalborg, Denmark
        • 135.312.45005 Boehringer Ingelheim Investigational Site
      • Aarhus, Denmark
        • 135.312.45002 Boehringer Ingelheim Investigational Site
      • Copenhagen NV, Denmark
        • 135.312.45001 Boehringer Ingelheim Investigational Site
      • Glostrup, Denmark
        • 135.312.45004 Boehringer Ingelheim Investigational Site
  • Finland
      • Helsinki, Finland
        • 135.312.35801 Boehringer Ingelheim Investigational Site
      • Kuopio, Finland
        • 135.312.35805 Boehringer Ingelheim Investigational Site
      • Turku, Finland
        • 135.312.35802 Boehringer Ingelheim Investigational Site
  • France
      • Auch, France
        • 135.312.33009 Boehringer Ingelheim Investigational Site
      • Besançon cedex, France
        • 135.312.33016 Boehringer Ingelheim Investigational Site
      • Bordeaux cedex, France
        • 135.312.33013 Boehringer Ingelheim Investigational Site
      • Bourg en Bresse, France
        • 135.312.33017 Boehringer Ingelheim Investigational Site
      • Dijon cedex, France
        • 135.312.33008 Boehringer Ingelheim Investigational Site
      • Grenoble cédex 9, France
        • 135.312.33014 Boehringer Ingelheim Investigational Site
      • Lille cedex, France
        • 135.312.33015 Boehringer Ingelheim Investigational Site
      • Limoges cedex 1, France
        • 135.312.33019 Boehringer Ingelheim Investigational Site
      • Lyon Cedex, France
        • 135.312.33001 Boehringer Ingelheim Investigational Site
      • Mantes la Jolie, France
        • 135.312.33024 Boehringer Ingelheim Investigational Site
      • Meaux, France
        • 135.312.33021 Boehringer Ingelheim Investigational Site
      • Montpellier, France
        • 135.312.33002 Boehringer Ingelheim Investigational Site
      • Nancy, France
        • 135.312.33004 Boehringer Ingelheim Investigational Site
      • Nice cedex 1, France
        • 135.312.33003 Boehringer Ingelheim Investigational Site
      • Paris, France
        • 135.312.33006 Boehringer Ingelheim Investigational Site
      • Paris cedex 18, France
        • 135.312.33007 Boehringer Ingelheim Investigational Site
      • Pau cedex, France
        • 135.312.33020 Boehringer Ingelheim Investigational Site
      • Perpignan cedex, France
        • 135.312.33018 Boehringer Ingelheim Investigational Site
      • Pontoise, France
        • 135.312.33023 Boehringer Ingelheim Investigational Site
      • Saint Herblain, France
        • 135.312.33010 Boehringer Ingelheim Investigational Site
      • Toulouse cedex 9, France
        • 135.312.33005 Boehringer Ingelheim Investigational Site
      • Toulouse cedex 9, France
        • 135.312.33012 Boehringer Ingelheim Investigational Site
      • Tours cedex 9, France
        • 135.312.33011 Boehringer Ingelheim Investigational Site
      • Versailles, France
        • 135.312.33022 Boehringer Ingelheim Investigational Site
  • Germany
      • Altenburg, Germany
        • 135.312.49031 Boehringer Ingelheim Investigational Site
      • Bamberg, Germany
        • 135.312.49011 Boehringer Ingelheim Investigational Site
      • Beeskow, Germany
        • 135.312.49037 Boehringer Ingelheim Investigational Site
      • Bochum, Germany
        • 135.312.49017 Boehringer Ingelheim Investigational Site
      • Frankfurt/Main, Germany
        • 135.312.49038 Boehringer Ingelheim Investigational Site
      • Hamburg, Germany
        • 135.312.49041 Boehringer Ingelheim Investigational Site
      • Hannover, Germany
        • 135.312.49023 Boehringer Ingelheim Investigational Site
      • Heidelberg, Germany
        • 135.312.49001 Boehringer Ingelheim Investigational Site
      • Köln, Germany
        • 135.312.49008 Boehringer Ingelheim Investigational Site
      • Leipzig, Germany
        • 135.312.49014 Boehringer Ingelheim Investigational Site
      • Ludwigshafen am Rhein, Germany
        • 135.312.49020 Boehringer Ingelheim Investigational Site
      • Magdeburg, Germany
        • 135.312.49004 Boehringer Ingelheim Investigational Site
      • Mainz, Germany
        • 135.312.49003 Boehringer Ingelheim Investigational Site
      • Mannheim, Germany
        • 135.312.49018 Boehringer Ingelheim Investigational Site
      • Minden, Germany
        • 135.312.49002 Boehringer Ingelheim Investigational Site
      • München, Germany
        • 135.312.49006 Boehringer Ingelheim Investigational Site
      • Siegen, Germany
        • 135.312.49005 Boehringer Ingelheim Investigational Site
      • Teupitz, Germany
        • 135.312.49025 Boehringer Ingelheim Investigational Site
      • Wiesbaden, Germany
        • 135.312.49009 Boehringer Ingelheim Investigational Site
  • Greece
      • Athens, Greece
        • 135.312.30004 Boehringer Ingelheim Investigational Site
      • Larissa, Greece
        • 135.312.30005 Boehringer Ingelheim Investigational Site
      • Thessaloniki, Greece
        • 135.312.30002 Boehringer Ingelheim Investigational Site
  • Hungary
      • Debrecen, Hungary
        • 135.312.36002 University of Debrecen
      • Györ, Hungary
        • 135.312.36001 Aladár Petz County Hospital
      • Miskolc, Hungary
        • 135.312.36006 BAZ County and Teaching Hospital
  • Italy
      • Coppito (aq), Italy
        • 135.312.39020 Università degli Studi
      • Firenze, Italy
        • 135.312.39013 A. O. Universitaria di Careggi
      • Firenze, Italy
        • 135.312.39019 Ospedale Santa Maria Annunziata
      • Imperia, Italy
        • 135.312.39022 Ospedale di Imperia
      • Milano, Italy
        • 135.312.39024 Istituto Scientifico San Raffaele
      • Padova, Italy
        • 135.312.39002 A. O. di Padova - Policlinico Universitario
      • Perugia, Italy
        • 135.312.39005 A. O. di Perugia - Policlinico Monteluce
      • Piacenza, Italy
        • 135.312.39023 P. O. di Piacenza
      • Pietra Ligure (sv), Italy
        • 135.312.39016 A. O. Ospedale Santa Corona
      • Pisa, Italy
        • 135.312.39006 Ospedale Santa Chiara
      • Reggio Emilia, Italy
        • 135.312.39003 A. O. Arcispedale "Santa Maria Nuova"
      • Roma, Italy
        • 135.312.39001 A. O. Policlinico Umberto I
      • Roma, Italy
        • 135.312.39025 Università di Roma "La Sapienza"
      • Udine, Italy
        • 135.312.39018 Ospedale S. Maria della Misericordia
      • Verona, Italy
        • 135.312.39009 Ospedale Maggiore di BorgoTrento
      • Vicenza, Italy
        • 135.312.39004 Ospedale Civile
  • Netherlands
      • Amsterdam, Netherlands
        • 135.312.31001
      • Enschede, Netherlands
        • 135.312.31007 Medisch Spectrum Twente
  • Norway
      • Bergen, Norway
        • 135.312.47001 Boehringer Ingelheim Investigational Site
      • Trondheim, Norway
        • 135.312.47003 Boehringer Ingelheim Investigational Site
      • Tønsberg, Norway
        • 135.312.47006 Boehringer Ingelheim Investigational Site
  • Poland
      • Gdansk, Poland
        • 135.312.48004 Medical University of Gdansk
      • Katowice, Poland
        • 135.312.48005 Dept. of Neurology, Regenerative and Cerebrovascular Disease
      • Opole, Poland
        • 135.312.48006 Wojewodship Specialistic Neuropsychiatric Centre in Opole
      • Warsaw, Poland
        • 135.312.48001 Institute of Psychiatry & Neurology in Warsaw
      • Warsaw, Poland
        • 135.312.48002 Dr. Anna Gostynska Wolski Hospital
  • Portugal
      • Coimbra, Portugal
        • 135.312.35101 Hospitais da Universidade de Coimbra
      • Lisboa, Portugal
        • 135.312.35106 Hospital de Santa Maria
      • Porto, Portugal
        • 135.312.35102 Hospital de Santo António
      • Santa Maria da Feira, Portugal
        • 135.312.35105 Hospital de São Sebastião, EPE
  • Slovakia
      • Bratislava, Slovakia
        • 135.312.42103 NEURON PLUS s.r.o
      • Levoca, Slovakia
        • 135.312.42102 Hospital Levoca
      • Martin, Slovakia
        • 135.312.42104 Jessenius Faculty of Medicine Commenius University
      • Nitra, Slovakia
        • 135.312.42101 Faculty Hospital
      • Trnava, Slovakia
        • 135.312.42105 Boehringer Ingelheim Investigational Site
  • Spain
      • Albacete, Spain
        • 135.312.34019 Boehringer Ingelheim Investigational Site
      • Badalona / Barcelona, Spain
        • 135.312.34006 Boehringer Ingelheim Investigational Site
      • Barcelona, Spain
        • 135.312.34001 Boehringer Ingelheim Investigational Site
      • Barcelona, Spain
        • 135.312.34002 Boehringer Ingelheim Investigational Site
      • Barcelona, Spain
        • 135.312.34003 Boehringer Ingelheim Investigational Site
      • Bilbao, Spain
        • 135.312.34011 Boehringer Ingelheim Investigational Site
      • Girona, Spain
        • 135.312.34007 Boehringer Ingelheim Investigational Site
      • Madrid, Spain
        • 135.312.34009 Boehringer Ingelheim Investigational Site
      • Madrid, Spain
        • 135.312.34010 Boehringer Ingelheim Investigational Site
      • Madrid, Spain
        • 135.312.34020 Boehringer Ingelheim Investigational Site
      • Santiago de Compostela, Spain
        • 135.312.34017 Boehringer Ingelheim Investigational Site
      • Sevilla, Spain
        • 135.312.34018 Boehringer Ingelheim Investigational Site
      • Zaragoza, Spain
        • 135.312.34014 Boehringer Ingelheim Investigational Site
  • Sweden
      • Lidköping, Sweden
        • 135.312.46007 Boehringer Ingelheim Investigational Site
      • Malmö, Sweden
        • 135.312.46003 Boehringer Ingelheim Investigational Site
      • Skövde, Sweden
        • 135.312.46005 Boehringer Ingelheim Investigational Site
      • Stockholm, Sweden
        • 135.312.46002 Boehringer Ingelheim Investigational Site
      • Stockholm, Sweden
        • 135.312.46004 Boehringer Ingelheim Investigational Site
  • Switzerland
      • Aarau, Switzerland
        • 135.312.41003 Boehringer Ingelheim Investigational Site
      • Basel, Switzerland
        • 135.312.41001 Boehringer Ingelheim Investigational Site
      • Lausanne, Switzerland
        • 135.312.41004 Boehringer Ingelheim Investigational Site
      • St. Gallen, Switzerland
        • 135.312.41002 Boehringer Ingelheim Investigational Site
  • United Kingdom
      • Aberdeen, United Kingdom
        • 135.312.44025 Boehringer Ingelheim Investigational Site
      • Bournemouth, United Kingdom
        • 135.312.44002 Boehringer Ingelheim Investigational Site
      • Cambridge, United Kingdom
        • 135.312.44023 Boehringer Ingelheim Investigational Site
      • Dundee, United Kingdom
        • 135.312.44026 Boehringer Ingelheim Investigational Site
      • Glasgow, United Kingdom
        • 135.312.44003 Boehringer Ingelheim Investigational Site
      • Glasgow, United Kingdom
        • 135.312.44006 Boehringer Ingelheim Investigational Site
      • Glasgow, United Kingdom
        • 135.312.44024 Boehringer Ingelheim Investigational Site
      • Liverpool, United Kingdom
        • 135.312.44018 Boehringer Ingelheim Investigational Site
      • London, United Kingdom
        • 135.312.44030 Boehringer Ingelheim Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Female or male inpatients
  • Age: 18 - 80 years.
  • Clinical diagnosis of ischemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect. Ischemic stroke is defined as an event characterized by the sudden onset of an acute focal neurologic deficit presumed to be due to cerebral ischemia after CT scan excludes hemorrhage.
  • Onset of symptoms between 3 and 4 hours prior to initiation of administration of study drug.
  • Stroke symptoms are to be present for at least 30 minutes and have not significantly improved before treatment. Symptoms must be distinguishable from an episode of generalized ischemia (i.e. syncope), seizure, or migraine disorder.
  • Patient is willing to participate voluntarily and to sign a written patient informed consent. Informed consent will be obtained from each patient or the subject's legally authorized representative or relatives, or deferred where applicable, according to the regulatory and legal requirements of the participating country.
  • Patients who are unable to sign but who are able to understand the meaning of participation in the study may give an oral witnessed informed consent. These patients have to make clear undoubtfully that they are willing to participate voluntarily and must be able to understand an explanation of the contents of he information sheet.
  • Willingness and ability to comply with the protocol.

Exclusion Criteria:

  • Evidence of intracranial hemorrhage (ICH) on the CT-scan.
  • Symptoms of ischaemic attack began more than 4 hours and 30 minutes prior to infusion start or when time of symptom onset is unknown.
  • Minor neurological deficit or symptoms rapidly improving before start of infusion.
  • Severe stroke as assessed clinically (e.g. NIHSS>25) and/or by appropriate imaging techniques.
  • Epileptic seizure at onset of stroke
  • Symptoms suggestive of subarachnoid haemorrhage, even if the CT-scan is normal.
  • Administration of heparin within the previous 48 hours and a thromboplastin time exceeding the upper limit of normal for laboratory
  • History of prior stroke and concomitant diabetes. * Prior stroke within the last 3 months
  • Platelet below 100,000/mm3. * Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg, or aggressive management (IV medication) necessary to reduce BP to these limits.
  • Blood glucose <50 or > 400 mg/dl (< 2.77 or > 22.15 mmol / l). * Known haemorraghic diathesis
  • Patients receiving oral anticoagulants. * Manifest or recent severe or dangerous bleeding
  • Known history of or suspected intracranial haemorrhage
  • Suspected subarachnoid haemorrhage or condition after subarachnoid haemorrhage from aneurysm
  • History of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
  • Haemorrhagic retinopathy,e.g. in diabetes (vision disturbances may indicate haemorrhagic retinopathy)
  • Recent (less than 10 days) traumatic external heart massage, obstetrical delivery, recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein puncture.
  • bacterial endocarditis, pericarditis.* Acute pancreatitis
  • Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial- aneurysm, arterial/venous malformation
  • Neoplasm with increased bleeding risk

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
modified Rankin scale (mRS) 0-1 (favourable outcome) at Day 90
Time Frame: at day 90
at day 90

Secondary Outcome Measures

Outcome Measure
Time Frame
Global outcome of four neurologic and disability scores combined
Time Frame: at day 90
at day 90

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2003

Primary Completion (Actual)

February 1, 2008

Study Registration Dates

First Submitted

September 9, 2005

First Submitted That Met QC Criteria

September 9, 2005

First Posted (Estimate)

September 12, 2005

Study Record Updates

Last Update Posted (Estimate)

May 16, 2014

Last Update Submitted That Met QC Criteria

April 30, 2014

Last Verified

April 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 135.312

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebrovascular Accident

Clinical Trials on rt-PA 0.9 mg/kg verum or placebo Intravenous

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe